Our Medical Advisory Council

The NLMSF Board is pleased to announce the formation of a new Medical Advisory Committee for the NLMSF.  We are honored that several of the finest researchers and clinicians in the field of sarcoma have agreed to serve on our Medical Advisory Committee.  The Committee is presently composed of 16 members including its Chairman, NLMSF Board Member, LMS Survivor, Mitchell D. Achee, MD, a Diagnostic Radiologist Practicing in Denver, Colorado.

mitch-pic

Dr.  MITCHELL D. ACHEE, M.D.

Board Certified Diagnostic Radiologist, Denver, Colorado
University of Virginia School of Medicine Graduate M.D. (1977) Medical Internship and Residency in Diagnostic Radiology at Fitzsimons Army Medical Center, Aurora, ColoradoChair: Medical Advisory Committee, National Leiomyosarcoma Foundation

Dr. Achee, a Leiomyosarcoma survivor, diagnosed in 2011, has been in private practice for more than 25 years with Diversified Radiology of Colorado, P. C., a subspecialty radiology group of more than 60 radiologists in Denver, Colorado.  Dr. Achee has served in both active duty and in the reserves in the Army.  He served as Chief of the Diagnostic Branch, Dept. of Radiology at Fitzsimmons Army Medical Center. He was Chief of the Dept. of Radiology at the Franklin Clinic of the Colorado Permanente Medical Group, P. C. in Denver.  He has held many leadership positions after his Army service:  Chairman, Dept. of Radiology / Chairman, Credentials Committee at Centura Avista Hospital;  President of the Medical Staff, Centura Avista Hospital;  Chair, Dept. of Radiology at Exempla St. Joseph Hospital in Denver;  Vice-President of operations and Hospital Affairs for Diversified Radiology of Colorado (encompassing 12 hospitals, 50 radiologists);  Medical Advisory Committee for United Healthcare of Colorado;  Denver Medical Society Board of Directors member.Currently, Dr. Achee is a member of the Connective Tissue Oncology Society (CTOS).  He has focused on sarcoma patient support, advocacy, and education, as well as sarcoma research.  He, along with his wife, established a patient support and education website (www.lmslifeline.com) as well as assisted in establishing the Rocky Mountain LMS Support Network for LMS patients throughout Colorado.  Dr. Achee is a Sarcoma Alliance Board member.

Laurence H Baker DO

Professor   Michican Medicine – Sarcoma
University of Michigan Comprehensive Cancer Center Specialties:
Osteopathic Board of Oncology, Internal Medicine   51 years in practice
Area of Practice:
Survivorship for patients with soft tissue and bone sarcomas, collaborative clinical trials.  The visionary for initiating the Sarcoma Alliance Through Research Collaboration (SARC) for the
advancement of sarcoma research and recognition of new researchers interested in sarcoma research.

Kenneth Cardona, MD FACS
Associate Professor of Surgery
Division of Surgical Oncology
Winship Cancer Institute
Emory University Hospital Midtown

Dr. Cardona is a board certified surgeon and surgical oncologist who specializes in the management of complex gastrointestinal malignancies (such as stomach, pancreas, and liver cancers) and is an expert in the treatment of sarcomas.
Dr. Cardona is a leader and active member of both the Gastrointestinal Oncology and Sarcoma Workgroups at Emory University Hospital Midtown and collaborates with medical and radiation oncologists, gastroenterologists, and interventional radiologists to develop an individualized, multidisciplinary treatment plan for each patient.

 

Dr. Sant P Chawla

Sant P. Chawla, M.D. holds medical licensures in both Texas and California, and he is board certified in Internal Medicine and Medical Oncology. He is a pioneering physician whose work in sarcoma oncology has brought him several accolades and recognition as one of the world’s leading authorities in medical treatment and clinical research for bone and soft-tissue sarcomas and sarcoma therapy. DrChawla heads the Sarcoma Oncology Center in Santa Monica, CA where he leads clinical cancer research efforts and conducted groundbreaking clinical research in pancreatic carcinoma, gynecologic tumors, breast cancer, glioblastoma, malignant peripheral nerve sheath tumors, lung cancer and gastrointestinal tumors.
DrChawla serves on the clinical faculty of numerous prestigious cancer centers, including UCLA, USC, John Wayne Cancer Institute at St. John’s Hospital; he is an adjunct associate professor at Stanford University and the University of Texas, M.D. Anderson Cancer Center; and he is a medical oncologist at Cedars Sinai Comprehensive Cancer Center. Over his 30 years of medical and clinical research experience, DrChawla’s research has been a foundation for further breakthroughs in cancer treatment.
DrChawla’s pioneering work in cancer research began in the 1980s when he contributed to breakthroughs in the treatment of young patients with osteosarcoma. He innovated limb-saving treatment for these young patients where amputation was previously the only option. Since that time, he has conducted over 60 clinical trials for cancer drugs, a number of which have been approved by the FDA and EMA. Most recently, the Center completed a breakthrough Phase II trial for Aldoxorubicin (second line for soft tissue sarcomas). The groundbreaking research reported that patients treated with Aldoxorubicin had significantly increased progression-free and overall survival rates without any observed cardiotoxicity.

edwin

Edwin Choy, M.D. / Ph.D. (Medical Oncologist)


Assistant Professor of Medicine Harvard Medical School
Dana Farber/Harvard Cancer Center
Massachusetts General Hospital
Director of Sarcoma Clinical Research
Clinical Director of Sarcoma Oncology

Edwin Choy, MD, PhD, is an esteemed clinical oncologist in the MGH Center for Sarcoma and Connective Tissue Oncology. As the Director of Sarcoma Research at the Division of Hematology Oncology at MGH, he specializes in the medical management of patients with sarcomas and maintains an active research focus that encompasses diverse areas of sarcoma therapy, ranging from use of nanotechnology and translational research aimed at developing new molecular therapies for treating sarcomas to preclinical studies using cell lines and animal models to better understand biochemical predictors of sarcoma therapy.

His training includes molecular biophysics and biochemistry with post-doctoral in internal medicine, hematology/oncology and a program in Medical Genetics through the Broad Institute of Harvard and Massachusetts Institute of Technology.

Dr. Choy serves as an advisor on several Scientific Advisory Boards including Liddy Shriver, Amgen, Pfizer, and Bayer.  He was the Clinical Trial Project Leader for NCIs Specialized Program of Research Excellence (SPORE) in collaboration with the Sarcoma Alliance and Medical Co-Chair for Clinical Trial ARST 1321.

chugh_8

Dr. Rashmi Chugh, M.D.

Rashmi  Chugh, M.D. (Medical Oncologist)
Clinical Assistant Professor of Internal Medicine—Hematology/Oncology
University of Michigan Health System
Washington University School of Medicine in St. Louis

CERTIFICATIONS & LICENSURE
MI State Medical License 2001 – 2017
American Board of Internal Medicine-Internal Medicine, 2001
American Board of Internal Medicine-Medical Oncology, 2006

Dr. Rashmi Chugh is a well-respected medical oncologist in Ann Arbor, Michigan, and is affiliated with multiple hospitals in the area, including University of Michigan Hospitals and Health Centers and Veterans Affairs Ann Arbor Healthcare System. She received her medical degree from Washington University School of Medicine in St. Louis and her residency at the University of Michigan in Internal Medicine in 2002.  Her fellowship followed in Hematology/Medical Oncology, University of Michigan Health System, 2005, and she has been in practice for 17 years.

Dr. Chugh was recognized for her research on CMS Meaningful Use Stage 1 Certification, EpicCare Ambulatory EMR, Epic Systems Corporation in 2012 and CMS Meaningful Use Stage 1 Certification, EpicCare Ambulatory EMR, Epic Systems Corporation in 2013.

She is one of 31 doctors at University of Michigan Hospitals and Health Centers and one of 30 at Veterans Affairs Ann Arbor Healthcare System who specializes in Medical Oncology. She conducts clinical trials of investigational agents or novel combinations in sarcoma patients.

Mihaela Druta, MD

Dr. Druta earned her MD degree from the University of Medicine and Pharmacy Carol Davila, Romainia.  She completed an Internal Medicine Residency and Hematology/Medical Oncology Fellowship at the University of South Florida at Moffitt Cancer Center.  Dr. Druta most recently completed a Sarcoma Medical Oncology Fellowship (Willie Tichenor Sarcoma Fellowship) at MD Anderson Cancer Center. Dr. Druta’s clinical interest is in the development of clinical trials focusing on targeted therapeutics specific to sarcoma patients.  Her research interest is in the translational aspects of sarcoma biology focusing specifically on Well-differentiated/Differential Liposarcoma and Leiomyosarcoma.

jonathan_fletcher-photo

Dr. Jonathan Fletcher
Assoc. Professor of Pathology

Harvard Medical Pathology – Dana FarberBrighan & Women’s Cancer Center

DF/HCC PROGRAM AFFILIATION

There are five areas of research focus in our laboratory. First is the identification of novel therapeutic targets amongst the tyrosine kinase family of proteins. These efforts focus on sarcomas, mesothelioma, and other solid tumors. Second is discovery of oncogenic mechanisms and therapeutic targets in leiomyosarcoma, gastrointestinal stromal tumor, and mesothelioma. Third is use of molecular cytogenetic methods to identify novel oncogenes in solid tumors. Fourth is development of novel approaches to administering targeted therapies in cancer. Fifth is characterization of response and resistance mechanisms to targeted therapies in cancer.
Dr. Suzanne George, Dana Farber Cancer Institute
Co-Clinical Director, Center for Sarcoma and Bone Oncology
Senior Physician
Associate Professor of Medicine, Harvard Medical School
Dr. Rebecca Gladdy
CLINICIAN SCIENTIST
Lunenfeld-Tanenbaum
Research InstituteResearchers have recognized that there is an urgent need to develop subtype-specific molecularly targeted therapeutics that can provide new treatment options unique to each histologic type of sarcoma.
Our program has focused on developing novel therapies for: rhabdomyosarcoma, a tumor mainly found in children and adult sarcomas including leiomyosarcoma and undifferentiated pleomorphic sarcoma.
 

Erlinda Maria Gordon, M.D.

Dr. Gordon is an experienced Pediatric Hematologist-Oncologist, cancer drug developer, biopharmaceutical founder and executive with a proven track record in translational biomedical research, patient care and cancer drug development.

A Diplomate of the American Board of Pediatric Hematology/Oncology, Dr. Gordon was a Tenured Associate Professor for 24 years and is a Professor Emeritus at the USC Keck School of Medicine, Los Angeles, California. She is co-inventor of more than 150 patents in biomedical research, and patented the first targeted gene delivery system for cancer in the USA, Europe and the Philippines. She has authored more than 100 original peer-reviewed articles and served as Editor-in-Chief of the International Journal of Pediatric Hematology-Oncology, Director of the Red Cell Defects Program and the NIH-funded Comprehensive Hemophilia Center at Childrens Hospital of Los Angeles and the NIH-funded Children’s Oncology Group. Dr. Gordon was co-founder of two biotechnology companies and is a pioneer in the development of targeted gene therapy products. In her position as FDA liaison for these companies, Dr. Gordon gained FDA orphan drug approval and fast track designation for pancreatic cancer, soft tissue sarcoma and osteosarcoma and accelerated approval for Rexin-G, the world’s first targeted genetic medicine for cancer. At USC, Dr. Gordon licensed the First Academic Vector Production Unit at the Norris Comprehensive Cancer Center, served as its first Medical Director for eight years, and was the Gene Therapy Sponsor for clinical protocols using Targeted Genetic Medicines for Cancer. Dr. Gordon was the recipient of the Los Angeles Award for Excellence in Biotechnology Research, the National Institutes of Health Research Career Development Award and NIH/FDA funded grant awards.Currently, Dr. Gordon serves as the Director of Biological and Immunological Therapies and the Chairman of the NIH-approved Institutional Biosafety Committee at the Sarcoma Oncology Center in Santa Monica, California.A native of the Philippines and an alumna of the University of Santo Tomas Medical College of Medicine and Surgery, where she received her medical degree, Dr. Gordon is nominee for the prestigious Thomas Award for Excellence in Research to be awarded in 2016.

Dr. Kenneth Gundle

Dr. Kenneth Gundle is an orthopedic surgeon in Portland, Oregon and is affiliated with OHSU Hospital. He received his medical degree from Harvard Medical School and has been in practice for 6-10 years. He is one of 19 doctors at OHSU Hospital who specialize in Orthopedic Surgery.

Subspecialties: General Orthopedic Surgery, Musculoskeletal Oncology/Cancer

Dr. Kenneth Robert Gundle is trained in the preservation, investigation and restoration of the form and function of the extremities, spine and associated structures by medical, surgical and physical means including the patients with musculoskeletal problems which include congenital deformities, trauma, infections, tumors, metabolic disturbances of the musculoskeletal system, deformities, injuries and degenerative diseases of the spine, hands, feet, knee, hip, shoulder and elbow in children and adults. Patients with primary and secondary muscular problems and the effects of central or peripheral nervous system lesions of the musculoskeletal system are also concerned.

 

Dr. Robin Jones
Dr. Robin Jones is a medical oncologist with a specialist interest in bone and soft tissue sarcomas. He has been principal investigator on numerous phase I, II and III trials.
He completed his medical training at Guy’s and St Thomas’ Hospital and his oncology training at The Royal Marsden. His postgraduate research degree, with Professor Dowsett at the ICR, evaluated potential predictive and prognostic factors in breast cancer patients treated with neoadjuvant chemotherapy.
He is a member of the Sarcoma Alliance for Research through Collaboration (SARC) concept review committee, the American Joint Committee on Cancer (AJCC) soft tissue sarcoma staging panel and the American Society of Clinical Oncology (ASCO) Educational Committee, and was previously a member of the National Comprehensive Cancer Network (NCCN) Bone Tumour Panel.
David Kirsch MD, PhD
Barbara Levine University Professor
Professor and Vice Chair for Basic & Translational Research, Department of Radiation Oncology
Professor, Department of Pharmacology & Cancer Biology
Kirsch Lab-  Duke University Medical Center, Duke Cancer Institute
Durham, NC

lazaar

Dr. ALEXANDER LAZAR, M.D. / Ph.D.


Associate Professor, Dept. of Pathology, Division of Pathology/Lab Medicine, Director, Dept. of Pathology, University of Texas MD Anderson Cancer Center University of Texas, MD Anderson Cancer Center, Houston, Texas Selective (soft Tissue) Pathology Fellowship Training Program, Houston, Texas University of Texas, Southwestern Medical Center Graduate (MD/PhD program, 2000)
Clinical Residency, Anatomic Pathology, Brigham and Women’s Hospital, Boston, MA University of Texas Southwestern Medical Center, Dallas, TX, Medical Scientist Training Program (2002)
University of Texas Southwestern Graduate School of Biomedical Science, Dallas, Texas (2002)

Dr. Lazar is a distinguished medical pathologist with considerable background and training in the area of soft tissue sarcoma. He has had an administrative appointment as Director, Dept. of Pathology at M.D. Anderson with selective Soft Tissue Pathology Fellowship training, as well as a Faculty member at M. D. Anderson’s Sarcoma Research Center. Postgraduate training has been extensive, with a Clinical Fellowship, Soft Tissue Pathology at Brigham and Women’s Hospital, Boston, MA from 2002-2003. He has also been a committee member, American Joint Cancer Committee Soft Tissue Sarcoma (AJCC), 6th/7th Edition Task Force from 2007 to the present. Dr. Lazar has been a committee member of the Cancer Committee, Sarcoma Section, College of American Pathologists (CAP, since 2007.  He is also a member of the Sarcoma Multidisciplinary Clinical Center, Steering Committee since 2006, and is on the Teaching Faculty, Baylor Molecular Genetics, Baylor College of Medicine as of 2009.

Dr. Lazar was invited as a consultant to the First International Conference on Sarcoma Pathology, Miami, Florida, sponsored by the Office of Rare Diseases, NCI/NIH.  Dr. Lazar was a panelist by invitation-only to the roundtable event for approximately 50 international thought leaders to establish priorities for basis and translational research in 2009.

Dr. Robert Maki, MD

Sarcoma Program Leader/Medical Director
Center for Cancer Therapies
Monter Cancer Center

New Hyde Park, New York

Dr. Maki is an internationally -renowned sarcoma cancer physician and researcher, serving as the Director of Experimental Therapeutics of the Don Monti Division of Medical Oncology and Hematology at North Shore University Hospital and Long Island Jewish Medical Center, and Director of the Center for New Cancer Therapies at Northwell health Cancer Institute.

 Dr. Maki is a professor of hematology/oncology at the Hofstra Northwell School of Medicine and professor and member of the

National Cancer Institute-designated Cancer Center at CSHL.  He has extensive expertise and experience in the development of novel therapies for the treatment of soft tissue and bone sarcomas.  he oversees the expansion of the basic and translational sarcoma cancer research program in collaboration with CSHL.  He will be pursuing bench -to-bedside research and clinical trials to improve the outcome of patients with aggressive cancer using promising new agents.  He has dedicated his life to finding a cure for sarcoma.

unnamed-6

Dr. Sujana Movva  

Menatology/Oncology specialist/researcher Fox Chase Cancer Center – Philadelphia

As an Associate Professor/ oncologist, Dr. Movva is trained to diagnose and treat all types and forms of cancer. Dr. Movva may employ a variety of diagnostic tests such as biopsies, imaging tests, endoscopic tests and laboratory tests. She may offer treatment techniques such as chemotherapy or radiotherapy to combat the spread of cancer. Dr. Movva may also provide emotional and palliative care, ensuring patients experience the highest quality of life possible.

Dr. Sujana Movva is a medical oncologist in Philadelphia, Pennsylvania and is affiliated with Fox Chase Cancer Center-American Oncologic Hospital. She received her medical degree from University of Western Ontario and has been in practice between 11-20 years. She is one of 38 doctors at Fox Chase Cancer Center-American Oncologic Hospital who specialize in Medical Oncology.

As an oncologist, Dr. Movva is trained to diagnose and treat all types and forms of cancer. Dr. Movva may employ a variety of diagnostic tests such as biopsies, imaging tests, endoscopic tests and laboratory tests. She may offer treatment techniques such as chemotherapy or radiotherapy to combat the spread of cancer. Dr. Movva may also provide emotional and palliative care, ensuring patients experience the highest quality of life possible.

Dr. Scott H. Okuno, M.D.

Professor, Oncology
Medical Officer/Chair, Clinical Trials, SARC

Mayo Clinic, Rochester, MN

  • Medical officer, Sarcoma Alliance for Research Through Collaboration (SARC), 2011-present
  • Founding and active member, Midwest Sarcoma Trials Partnership, 2011-present
  • Active member, Sarcoma Working Group, Radiation Therapy Oncology Group, 2010-present
The research interests of Scott H. Okuno, M.D., include the management of patients with bone and soft tissue sarcomas, as well as head and neck cancers. His research encourages a multidisciplinary approach with surgeons and radiation oncologists.

Seth M. Pollack, MD
Clinical Expertise
Sarcoma, immune-based therapies
Title
  • Assistant Professor, University of Washington School of Medicine
  • Assistant Member, Fred Hutchinson Cancer Research Center
Dr. Pollack is a medical oncologist who treats adult patients with sarcoma.
Philosophy
My patient care philosophy is to provide care centered on the patient’s goals and desires. This begins with an education regarding their disease and treatment options. Every patient and every situation is different. I believe in fighting as hard as I can to help cure my patients. When this is not possible, I strive to help my patients live with an excellent quality of life for as long as possible.

unnamed-5

Dr.  RAPHAEL POLLOCK, M.D. / Ph.D., F>A>C>S

Surgical Oncologist
Director of the Division of Surgical Oncology at the Arthur G. Hospital, Ohio State University Comprehensive Cancer Center, Columbus, OhioPreviously Head of the Division of Surgery at the University of Texas, M.D. Anderson Cancer Center, Houston, with a 31-year affiliation with M.D. Anderson St. Louis University School of Medicine GraduateSurgical residencies at Rush-Presbyterian, St. Luke’s Medical Center, and University of Chicago Hospital

Dr. Pollock is world renowned and respected as a gifted cancer surgeon, researcher, and passionate educator of physicians in training.  Dr. Pollock is principal investigator of an $11.5 million National Cancer Institute (NCI) grant to support collaborative sarcoma (Programs of Research Excellence SPORE grant), awarded to the Sarcoma Alliance for Research for Collaboration (SARC).  His expertise and international reputation as an experienced surgical leader, as well as a distinguished academician and researcher, allow for the continued pairing of innovative surgical solutions with discoveries in the burgeoning field of cancer genomics.  The James Hospital is ranked by U. S. News and World Report as a “top of the top cancer hospitals in the nation,” and highly rated and funded by the NCI, with designation as one of only 41 National Cancer Institute-designated cancer centers to conduct both phase I and phase II clinical trials.

Dr. Pollock will also be a professor and the Director of the Division of Surgical at the Ohio State University Wexner Medical Center College of the Medicine’s department of surgery.  As an international researcher and academician, Dr. Pollock’s focus is research and development of therapeutics for tumor suppression in soft tissue sarcomas, with a multidisciplinary/multiple level treatment approach.

Dr. Richard Riedel, MD, Medical Oncologist,
Duke Cancer Center,Durham, NC
Associate Professor of Medicine / Research:  novel therapies of soft tissue and bone sarcomas

unnamed-2

Dr. Arun Singh Medical oncologist

Santa Monica, California UCLA Medical Center and UCLA Medical Center Santa Monica.

Dr. Arun Singh, assistant professor and Co-Director of the Medical Oncology Sarcoma Program, reviews the diagnosis, treatment and follow-up care of patients diagnosed with sarcomas – a spectrum of rare diseases. He discusses the importance of the multidisciplinary approach in caring for patients with these malignancies. He presents the evolving biologic understanding of sarcomas and how these new insights are leading to the development of the next generation of therapies for these patients. Additionally, Dr. Singh is the assistant professor in the Department of Medicine, Division of Hematology/Oncology at the David Geffen School of Medicine UCLA. Dr. Singh is a Hematologist and Medical Oncologist whose practice focuses on the treatment of bone and soft tissue sarcomas. Dr. Singh’s research focus is on developing novel therapies for patients with sarcomas. In the preclinical setting, he works on elucidating the mechanisms contributing to the promotion of growth in cancer cells and optimizing the use of targeted therapy in specific sarcoma subtypes. The insights gained from these efforts are then translated into the clinic in the form of new drugs in early stage Phase I and II clinical trials for sarcomas where there is an unmet clinical need.

Dr. Neeta Somaiah
Assistant Professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston

Hematology / Oncology

As a hematologist/oncologist in Texas, Dr. Somaiah is capable of diagnosing and treating patients with blood-related disorders, malignancies, or cancers. Dr. Somaiah may treat a range of conditions ranging from the common to the very rare and complex. As a result, Dr. Somaiah may provide care as part of a multidisciplinary team, working in conjunction with other specialists to ensure the highest possible standard of care.

 

Scott Michael Schuetze MD, PhD

Medical Oncology, Internal Medicine

Area of Practice: 

Soft tissue sarcoma,  Leiomyosarcoma, cranial base disorders, Ewing’s sarcoma, osteosarcoma, chondrosarcoma, giant cell tumor of bone and chordoma. Clinical trials of novel drugs for treatment of sarcoma.

William D. Tap, MD
Medical Oncologist
Chief, Sarcoma Medical Oncology Service
 

Brian Van Tine, MD, PhD

Medical Oncologist
Assistant professor of medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine
 

Research Interest

Clinical interest in the treatment of soft tissue and bone sarcomas. Research interest focuses on the study of the genomics and genetics of bone and soft tissue sarcomas. Using a combination of whole genomic sequencing and human in mouse xenografting, the Van Tine lab works to identify the druggable driving pathways for the treatment of sarcomas.
 
Dr.  Matt Van de Rijn
Professor of Pathology
Department of Pathology
Stanford University Medical Center
Our research focuses on the study of human tumors by using and developing a range of techniques on extracting genomic and proteomic data from patient derived archival material( formalin-fixed paraffin-embedded(FFPE)). We perform our genomic analyses include RNAseq, exome-seq and 3SEQ for gene expression profiling and mutation calling and followed by validation of the data with in situ hybridization or immunohistochemistry on tissue microarrays. Our goal is to find new diagnostic and prognostic markers in sarcoma and cancer, and to identify potential therapeutic targets.
Dr. Breelyn Wilky
Dr. Breelyn Wilky is a medical oncologist in Miami, Florida and is affiliated with multiple hospitals in the area, including Jackson Memorial Hospital and University of Miami Hospital. She received her medical degree from Rutgers Robert Wood Johnson Medical School and has been in practice between 6-10 years. She is one of 24 doctors at Jackson Memorial Hospital and one of 31 at University of Miami Hospital who specialize in Medical Oncology.
Dr.  Victor Villalobos,  University of Colorado Health Sciences, Sarcoma Center
As an oncologist, Dr. Villalobos is trained to diagnose and treat all types and forms of cancer. Dr. Villalobos may employ a variety of diagnostic tests such as biopsies, imaging tests, endoscopic tests and laboratory tests. He may offer treatment techniques such as chemotherapy or radiotherapy to combat the spread of cancer. Dr. Villalobos may also provide emotional and palliative care, ensuring patients experience the highest quality of life possible.  Dr. Villalobos is a research oncologist for a variety of sarcoma subtypes, including leiomyosarcoma.

Reaching For the Cure Together